Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short term Debt (2016 - 2023)

Amicus Therapeutics filings provide 13 years of Short term Debt readings, the most recent being $13.0 million for Q2 2023.

  • On a quarterly basis, Short term Debt fell 32.5% to $13.0 million in Q2 2023 year-over-year; TTM through Jun 2023 was $13.0 million, a 32.5% decrease, with the full-year FY2022 number at $21.4 million, up 13.32% from a year prior.
  • Short term Debt hit $13.0 million in Q2 2023 for Amicus Therapeutics, up from $12.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $21.4 million in Q4 2022 to a low of $8.9 million in Q4 2020.
  • Median Short term Debt over the past 4 years was $19.2 million (2022), compared with a mean of $17.2 million.
  • Biggest five-year swings in Short term Debt: skyrocketed 112.36% in 2021 and later crashed 33.85% in 2023.
  • Amicus Therapeutics' Short term Debt stood at $8.9 million in 2020, then skyrocketed by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • The last three reported values for Short term Debt were $13.0 million (Q2 2023), $12.7 million (Q1 2023), and $21.4 million (Q4 2022) per Business Quant data.